4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-20-060584
Chief R&D Officer sold 16,380 shares at $16.40 ($268,632)
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-11-23 | Sale : show line 1 in the form | −16,380 | $16.40 | $268,632 | 250,317 | D |
| Open-market sales · 16,380 sh · avg $16.40 · $268,632 | ||||||
Loading xslF345X03/doc4.xml…